| Ytd | -19.64% | |
| 1y | -79.43% |
| Open | 9.51 | Prev Close | 9.29 | Low | 9.51 | High | 9.51 | Mkt Cap | 10.64M |
| Vol | 1.18K | Avg Vol | 793.92K | EPS | -4.48 | P/E | -2.07 | Forward P/E | -0.29 |
| Beta | 1.38 | Short Ratio | 1.92 | Inst. Own | 0.51% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-22 | 50-d Avg | 11.42 | 200-d Avg | 13.62 | 1yr Est | 80.00 |
AKTX News
Gainers Jupiter Neurosciences (NASDAQ:JUNS) stock rose 36.4% to $0.23 during Tuesday's pre-mark
TAMPA, Fla. and LONDON, July 21, 2026 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), an
Gainers Crinetics Pharmaceuticals (NASDAQ:CRNX) shares moved upwards by 98.7% to $83.53 during Tues
Globally recognized leader in early-phase oncology clinical development and experimental therapeutic
Consolidated closing of recently announced $5.5 million PIPE led by existing investors, combined wit
Gainers Universe Pharmaceuticals (NASDAQ:UPC) stock moved upwards by 168.2% to $7.94 during Friday&
Discussion highlights growing importance on novel ADC payloads, and Akari's ASCO data in KRAS-driven
CEO Abizer Gaslightwala highlights promising ASCO data demonstrating synergy of AKTX-101 with adagas
US stock futures up, VNET Group shares down 3.8% after reporting Q1 loss of $(1.20) per share on $39
Discover why Akari Therapeutics PLC (NASDAQ: AKTX) stock is falling on Tuesday after last week's mas
Gainers: PHGE +97.3%, ARTL +74.8%, QTEX +52.4%, MNTX +34.4%, HLIT +28.3%, WOK +25%, CPSH +24.7%, COD
US stocks rose, Dow gained over 400 points. S&P 500 and NASDAQ also up. Health care shares jumpe
Akari Therapeutics Plc (NASDAQ:AKTX) shares are ripping higher after the company released preclinica
US stocks rise with the Dow gaining 250 points. Health care shares jump while energy stocks fall. BJ
Estee Lauder (EL) shares jumped 11.8% in pre-market trading after ending discussions with Puig. Othe
An ADC with a novel RNA spliceosome modulating payload PH1 paired with a KRAS inhibitor demonstrates
TAMPA, Fla. and LONDON, May 21, 2026 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), an
Live webcast fireside chat with Abizer Gaslightwala, President and Chief Executive Officer, on Wedne
Patent reinforces strategic foundation for lead ADC AKTX-101 and expanding ADC pipeline to new molec
Patent covers proprietary 2nd generation Thailanstatin analog payload designed for use in ADCs (anti
Akari Therapeutics PLC (NASDAQ: AKTX - Get Free Report) saw a significant growth in short interest i
Expands potential opportunities for AKTX-101 and its novel RNA splicing modulator payload in additio
Superior potency demonstrated versus leading TROP2 ADCs across bladder, lung and breast tumor models
CEO Abizer Gaslightwala discusses the Company's strategic partnership with WuXi XDC and its implicat
Strategic Partnership Enables Akari to Accelerate IND Filing By Late 2026 Strategic Partnership Enab
TAMPA, Fla. and LONDON, March 18, 2026 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a
TAMPA, Fla. and LONDON, March 17, 2026 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a
Akari Therapeutics PLC (NASDAQ: AKTX - Get Free Report) was the target of a significant decrease in